↓ Skip to main content

Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study

Overview of attention for article published in Frontiers in oncology, July 2021
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (62nd percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
1 X user
patent
1 patent

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study
Published in
Frontiers in oncology, July 2021
DOI 10.3389/fonc.2021.699323
Pubmed ID
Authors

Lili Zhang, Xiaohong Wu, Jun Zhou, Mingzhen Zhu, Hao Yu, Yusong Zhang, Yutian Zhao, Zhengxiang Han, Yujiang Guo, Xiaoqing Guan, Xufen Wang, Hong Xu, Li Sun, Jiaxin Zhang, Min Zhuang, Li Xie, Shiyou Yu, Ping Chen, Jifeng Feng

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 13 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 8%
Student > Bachelor 1 8%
Student > Postgraduate 1 8%
Student > Doctoral Student 1 8%
Unknown 9 69%
Readers by discipline Count As %
Medicine and Dentistry 2 15%
Immunology and Microbiology 1 8%
Design 1 8%
Unknown 9 69%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 April 2023.
All research outputs
#8,270,333
of 25,392,582 outputs
Outputs from Frontiers in oncology
#3,081
of 22,436 outputs
Outputs of similar age
#164,699
of 445,857 outputs
Outputs of similar age from Frontiers in oncology
#156
of 1,355 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 22,436 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 445,857 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
We're also able to compare this research output to 1,355 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.